Global Peptide Vaccine for Tumor Market Growth 2026-2032
The global Peptide Vaccine for Tumor market size is predicted to grow from US$ million in 2025 to US$ million in 2032; it is expected to grow at a CAGR of %from 2026 to 2032.
Peptide Vaccine for Tumor, is an anti-tumor therapeutic vaccine with the most researches, the best effect and the most mature technology among various therapeutic vaccines. Known as subunit vaccines, compared with traditional inactivated and attenuated vaccines, peptide vaccines can not only be used as preventive vaccines against infectious or non-infectious diseases, but also for the treatment of Alzheimer's disease, malignant tumors, etc.; peptide vaccines have become a new strategy for anti-tumor at present, and peptide anti-tumor therapeutic vaccines have accounted for the largest proportion of biotechnology anti-cancer new drugs under development.
United States market for Peptide Vaccine for Tumor is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for Peptide Vaccine for Tumor is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for Peptide Vaccine for Tumor is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key Peptide Vaccine for Tumor players cover AmbioPharm, Almac, ACT, Ultimovacs, Marker Therapeutics, Inc., etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
LP Information, Inc. (LPI) ' newest research report, the ?Peptide Vaccine for Tumor Industry Forecast? looks at past sales and reviews total world Peptide Vaccine for Tumor sales in 2025, providing a comprehensive analysis by region and market sector of projected Peptide Vaccine for Tumor sales for 2026 through 2032. With Peptide Vaccine for Tumor sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Peptide Vaccine for Tumor industry.
This Insight Report provides a comprehensive analysis of the global Peptide Vaccine for Tumor landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Peptide Vaccine for Tumor portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Peptide Vaccine for Tumor market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Peptide Vaccine for Tumor and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Peptide Vaccine for Tumor.
This report presents a comprehensive overview, market shares, and growth opportunities of Peptide Vaccine for Tumor market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Peptide Vaccine for Tumor, is an anti-tumor therapeutic vaccine with the most researches, the best effect and the most mature technology among various therapeutic vaccines. Known as subunit vaccines, compared with traditional inactivated and attenuated vaccines, peptide vaccines can not only be used as preventive vaccines against infectious or non-infectious diseases, but also for the treatment of Alzheimer's disease, malignant tumors, etc.; peptide vaccines have become a new strategy for anti-tumor at present, and peptide anti-tumor therapeutic vaccines have accounted for the largest proportion of biotechnology anti-cancer new drugs under development.
United States market for Peptide Vaccine for Tumor is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for Peptide Vaccine for Tumor is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for Peptide Vaccine for Tumor is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key Peptide Vaccine for Tumor players cover AmbioPharm, Almac, ACT, Ultimovacs, Marker Therapeutics, Inc., etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
LP Information, Inc. (LPI) ' newest research report, the ?Peptide Vaccine for Tumor Industry Forecast? looks at past sales and reviews total world Peptide Vaccine for Tumor sales in 2025, providing a comprehensive analysis by region and market sector of projected Peptide Vaccine for Tumor sales for 2026 through 2032. With Peptide Vaccine for Tumor sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Peptide Vaccine for Tumor industry.
This Insight Report provides a comprehensive analysis of the global Peptide Vaccine for Tumor landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Peptide Vaccine for Tumor portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Peptide Vaccine for Tumor market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Peptide Vaccine for Tumor and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Peptide Vaccine for Tumor.
This report presents a comprehensive overview, market shares, and growth opportunities of Peptide Vaccine for Tumor market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- Synthetic Polypeptide Vaccines
- Recombinant Polypeptide Vaccine
- Others
- Infectious Disease Prevention
- Cancer Immunotherapy
- Others
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- AmbioPharm
- Almac
- ACT
- Ultimovacs
- Marker Therapeutics, Inc.
- Immatics
- OncoPep
- Anergis
- Sellas Life Sciences
- What is the 10-year outlook for the global Peptide Vaccine for Tumor market?
- What factors are driving Peptide Vaccine for Tumor market growth, globally and by region?
- Which technologies are poised for the fastest growth by market and region?
- How do Peptide Vaccine for Tumor market opportunities vary by end market size?
- How does Peptide Vaccine for Tumor break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Peptide Vaccine for Tumor Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Peptide Vaccine for Tumor by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Peptide Vaccine for Tumor by Country/Region, 2021, 2025 & 2032
2.2 Peptide Vaccine for Tumor Segment by Type
2.2.1 Synthetic Polypeptide Vaccines
2.2.2 Recombinant Polypeptide Vaccine
2.2.3 Others
2.2.4 Peptide Vaccine for Tumor Sales by Type
2.2.4.1 Global Peptide Vaccine for Tumor Sales Market Share by Type (2021-2026)
2.2.4.2 Global Peptide Vaccine for Tumor Revenue and Market Share by Type (2021-2026)
2.2.4.3 Global Peptide Vaccine for Tumor Sale Price by Type (2021-2026)
2.3 Peptide Vaccine for Tumor Segment by Application
2.3.1 Infectious Disease Prevention
2.3.2 Cancer Immunotherapy
2.3.3 Others
2.3.4 Peptide Vaccine for Tumor Sales by Application
2.3.4.1 Global Peptide Vaccine for Tumor Sale Market Share by Application (2021-2026)
2.3.4.2 Global Peptide Vaccine for Tumor Revenue and Market Share by Application (2021-2026)
2.3.4.3 Global Peptide Vaccine for Tumor Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Peptide Vaccine for Tumor Breakdown Data by Company
3.1.1 Global Peptide Vaccine for Tumor Annual Sales by Company (2021-2026)
3.1.2 Global Peptide Vaccine for Tumor Sales Market Share by Company (2021-2026)
3.2 Global Peptide Vaccine for Tumor Annual Revenue by Company (2021-2026)
3.2.1 Global Peptide Vaccine for Tumor Revenue by Company (2021-2026)
3.2.2 Global Peptide Vaccine for Tumor Revenue Market Share by Company (2021-2026)
3.3 Global Peptide Vaccine for Tumor Sale Price by Company
3.4 Key Manufacturers Peptide Vaccine for Tumor Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Peptide Vaccine for Tumor Product Location Distribution
3.4.2 Players Peptide Vaccine for Tumor Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR PEPTIDE VACCINE FOR TUMOR BY GEOGRAPHIC REGION
4.1 World Historic Peptide Vaccine for Tumor Market Size by Geographic Region (2021-2026)
4.1.1 Global Peptide Vaccine for Tumor Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Peptide Vaccine for Tumor Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Peptide Vaccine for Tumor Market Size by Country/Region (2021-2026)
4.2.1 Global Peptide Vaccine for Tumor Annual Sales by Country/Region (2021-2026)
4.2.2 Global Peptide Vaccine for Tumor Annual Revenue by Country/Region (2021-2026)
4.3 Americas Peptide Vaccine for Tumor Sales Growth
4.4 APAC Peptide Vaccine for Tumor Sales Growth
4.5 Europe Peptide Vaccine for Tumor Sales Growth
4.6 Middle East & Africa Peptide Vaccine for Tumor Sales Growth
5 AMERICAS
5.1 Americas Peptide Vaccine for Tumor Sales by Country
5.1.1 Americas Peptide Vaccine for Tumor Sales by Country (2021-2026)
5.1.2 Americas Peptide Vaccine for Tumor Revenue by Country (2021-2026)
5.2 Americas Peptide Vaccine for Tumor Sales by Type (2021-2026)
5.3 Americas Peptide Vaccine for Tumor Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Peptide Vaccine for Tumor Sales by Region
6.1.1 APAC Peptide Vaccine for Tumor Sales by Region (2021-2026)
6.1.2 APAC Peptide Vaccine for Tumor Revenue by Region (2021-2026)
6.2 APAC Peptide Vaccine for Tumor Sales by Type (2021-2026)
6.3 APAC Peptide Vaccine for Tumor Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Peptide Vaccine for Tumor by Country
7.1.1 Europe Peptide Vaccine for Tumor Sales by Country (2021-2026)
7.1.2 Europe Peptide Vaccine for Tumor Revenue by Country (2021-2026)
7.2 Europe Peptide Vaccine for Tumor Sales by Type (2021-2026)
7.3 Europe Peptide Vaccine for Tumor Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Peptide Vaccine for Tumor by Country
8.1.1 Middle East & Africa Peptide Vaccine for Tumor Sales by Country (2021-2026)
8.1.2 Middle East & Africa Peptide Vaccine for Tumor Revenue by Country (2021-2026)
8.2 Middle East & Africa Peptide Vaccine for Tumor Sales by Type (2021-2026)
8.3 Middle East & Africa Peptide Vaccine for Tumor Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Peptide Vaccine for Tumor
10.3 Manufacturing Process Analysis of Peptide Vaccine for Tumor
10.4 Industry Chain Structure of Peptide Vaccine for Tumor
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Peptide Vaccine for Tumor Distributors
11.3 Peptide Vaccine for Tumor Customer
12 WORLD FORECAST REVIEW FOR PEPTIDE VACCINE FOR TUMOR BY GEOGRAPHIC REGION
12.1 Global Peptide Vaccine for Tumor Market Size Forecast by Region
12.1.1 Global Peptide Vaccine for Tumor Forecast by Region (2027-2032)
12.1.2 Global Peptide Vaccine for Tumor Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Peptide Vaccine for Tumor Forecast by Type (2027-2032)
12.7 Global Peptide Vaccine for Tumor Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 AmbioPharm
13.1.1 AmbioPharm Company Information
13.1.2 AmbioPharm Peptide Vaccine for Tumor Product Portfolios and Specifications
13.1.3 AmbioPharm Peptide Vaccine for Tumor Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 AmbioPharm Main Business Overview
13.1.5 AmbioPharm Latest Developments
13.2 Almac
13.2.1 Almac Company Information
13.2.2 Almac Peptide Vaccine for Tumor Product Portfolios and Specifications
13.2.3 Almac Peptide Vaccine for Tumor Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Almac Main Business Overview
13.2.5 Almac Latest Developments
13.3 ACT
13.3.1 ACT Company Information
13.3.2 ACT Peptide Vaccine for Tumor Product Portfolios and Specifications
13.3.3 ACT Peptide Vaccine for Tumor Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 ACT Main Business Overview
13.3.5 ACT Latest Developments
13.4 Ultimovacs
13.4.1 Ultimovacs Company Information
13.4.2 Ultimovacs Peptide Vaccine for Tumor Product Portfolios and Specifications
13.4.3 Ultimovacs Peptide Vaccine for Tumor Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Ultimovacs Main Business Overview
13.4.5 Ultimovacs Latest Developments
13.5 Marker Therapeutics, Inc.
13.5.1 Marker Therapeutics, Inc. Company Information
13.5.2 Marker Therapeutics, Inc. Peptide Vaccine for Tumor Product Portfolios and Specifications
13.5.3 Marker Therapeutics, Inc. Peptide Vaccine for Tumor Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Marker Therapeutics, Inc. Main Business Overview
13.5.5 Marker Therapeutics, Inc. Latest Developments
13.6 Immatics
13.6.1 Immatics Company Information
13.6.2 Immatics Peptide Vaccine for Tumor Product Portfolios and Specifications
13.6.3 Immatics Peptide Vaccine for Tumor Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Immatics Main Business Overview
13.6.5 Immatics Latest Developments
13.7 OncoPep
13.7.1 OncoPep Company Information
13.7.2 OncoPep Peptide Vaccine for Tumor Product Portfolios and Specifications
13.7.3 OncoPep Peptide Vaccine for Tumor Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 OncoPep Main Business Overview
13.7.5 OncoPep Latest Developments
13.8 Anergis
13.8.1 Anergis Company Information
13.8.2 Anergis Peptide Vaccine for Tumor Product Portfolios and Specifications
13.8.3 Anergis Peptide Vaccine for Tumor Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Anergis Main Business Overview
13.8.5 Anergis Latest Developments
13.9 Sellas Life Sciences
13.9.1 Sellas Life Sciences Company Information
13.9.2 Sellas Life Sciences Peptide Vaccine for Tumor Product Portfolios and Specifications
13.9.3 Sellas Life Sciences Peptide Vaccine for Tumor Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Sellas Life Sciences Main Business Overview
13.9.5 Sellas Life Sciences Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Peptide Vaccine for Tumor Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Peptide Vaccine for Tumor by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Peptide Vaccine for Tumor by Country/Region, 2021, 2025 & 2032
2.2 Peptide Vaccine for Tumor Segment by Type
2.2.1 Synthetic Polypeptide Vaccines
2.2.2 Recombinant Polypeptide Vaccine
2.2.3 Others
2.2.4 Peptide Vaccine for Tumor Sales by Type
2.2.4.1 Global Peptide Vaccine for Tumor Sales Market Share by Type (2021-2026)
2.2.4.2 Global Peptide Vaccine for Tumor Revenue and Market Share by Type (2021-2026)
2.2.4.3 Global Peptide Vaccine for Tumor Sale Price by Type (2021-2026)
2.3 Peptide Vaccine for Tumor Segment by Application
2.3.1 Infectious Disease Prevention
2.3.2 Cancer Immunotherapy
2.3.3 Others
2.3.4 Peptide Vaccine for Tumor Sales by Application
2.3.4.1 Global Peptide Vaccine for Tumor Sale Market Share by Application (2021-2026)
2.3.4.2 Global Peptide Vaccine for Tumor Revenue and Market Share by Application (2021-2026)
2.3.4.3 Global Peptide Vaccine for Tumor Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Peptide Vaccine for Tumor Breakdown Data by Company
3.1.1 Global Peptide Vaccine for Tumor Annual Sales by Company (2021-2026)
3.1.2 Global Peptide Vaccine for Tumor Sales Market Share by Company (2021-2026)
3.2 Global Peptide Vaccine for Tumor Annual Revenue by Company (2021-2026)
3.2.1 Global Peptide Vaccine for Tumor Revenue by Company (2021-2026)
3.2.2 Global Peptide Vaccine for Tumor Revenue Market Share by Company (2021-2026)
3.3 Global Peptide Vaccine for Tumor Sale Price by Company
3.4 Key Manufacturers Peptide Vaccine for Tumor Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Peptide Vaccine for Tumor Product Location Distribution
3.4.2 Players Peptide Vaccine for Tumor Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR PEPTIDE VACCINE FOR TUMOR BY GEOGRAPHIC REGION
4.1 World Historic Peptide Vaccine for Tumor Market Size by Geographic Region (2021-2026)
4.1.1 Global Peptide Vaccine for Tumor Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Peptide Vaccine for Tumor Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Peptide Vaccine for Tumor Market Size by Country/Region (2021-2026)
4.2.1 Global Peptide Vaccine for Tumor Annual Sales by Country/Region (2021-2026)
4.2.2 Global Peptide Vaccine for Tumor Annual Revenue by Country/Region (2021-2026)
4.3 Americas Peptide Vaccine for Tumor Sales Growth
4.4 APAC Peptide Vaccine for Tumor Sales Growth
4.5 Europe Peptide Vaccine for Tumor Sales Growth
4.6 Middle East & Africa Peptide Vaccine for Tumor Sales Growth
5 AMERICAS
5.1 Americas Peptide Vaccine for Tumor Sales by Country
5.1.1 Americas Peptide Vaccine for Tumor Sales by Country (2021-2026)
5.1.2 Americas Peptide Vaccine for Tumor Revenue by Country (2021-2026)
5.2 Americas Peptide Vaccine for Tumor Sales by Type (2021-2026)
5.3 Americas Peptide Vaccine for Tumor Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Peptide Vaccine for Tumor Sales by Region
6.1.1 APAC Peptide Vaccine for Tumor Sales by Region (2021-2026)
6.1.2 APAC Peptide Vaccine for Tumor Revenue by Region (2021-2026)
6.2 APAC Peptide Vaccine for Tumor Sales by Type (2021-2026)
6.3 APAC Peptide Vaccine for Tumor Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Peptide Vaccine for Tumor by Country
7.1.1 Europe Peptide Vaccine for Tumor Sales by Country (2021-2026)
7.1.2 Europe Peptide Vaccine for Tumor Revenue by Country (2021-2026)
7.2 Europe Peptide Vaccine for Tumor Sales by Type (2021-2026)
7.3 Europe Peptide Vaccine for Tumor Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Peptide Vaccine for Tumor by Country
8.1.1 Middle East & Africa Peptide Vaccine for Tumor Sales by Country (2021-2026)
8.1.2 Middle East & Africa Peptide Vaccine for Tumor Revenue by Country (2021-2026)
8.2 Middle East & Africa Peptide Vaccine for Tumor Sales by Type (2021-2026)
8.3 Middle East & Africa Peptide Vaccine for Tumor Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Peptide Vaccine for Tumor
10.3 Manufacturing Process Analysis of Peptide Vaccine for Tumor
10.4 Industry Chain Structure of Peptide Vaccine for Tumor
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Peptide Vaccine for Tumor Distributors
11.3 Peptide Vaccine for Tumor Customer
12 WORLD FORECAST REVIEW FOR PEPTIDE VACCINE FOR TUMOR BY GEOGRAPHIC REGION
12.1 Global Peptide Vaccine for Tumor Market Size Forecast by Region
12.1.1 Global Peptide Vaccine for Tumor Forecast by Region (2027-2032)
12.1.2 Global Peptide Vaccine for Tumor Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Peptide Vaccine for Tumor Forecast by Type (2027-2032)
12.7 Global Peptide Vaccine for Tumor Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 AmbioPharm
13.1.1 AmbioPharm Company Information
13.1.2 AmbioPharm Peptide Vaccine for Tumor Product Portfolios and Specifications
13.1.3 AmbioPharm Peptide Vaccine for Tumor Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 AmbioPharm Main Business Overview
13.1.5 AmbioPharm Latest Developments
13.2 Almac
13.2.1 Almac Company Information
13.2.2 Almac Peptide Vaccine for Tumor Product Portfolios and Specifications
13.2.3 Almac Peptide Vaccine for Tumor Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Almac Main Business Overview
13.2.5 Almac Latest Developments
13.3 ACT
13.3.1 ACT Company Information
13.3.2 ACT Peptide Vaccine for Tumor Product Portfolios and Specifications
13.3.3 ACT Peptide Vaccine for Tumor Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 ACT Main Business Overview
13.3.5 ACT Latest Developments
13.4 Ultimovacs
13.4.1 Ultimovacs Company Information
13.4.2 Ultimovacs Peptide Vaccine for Tumor Product Portfolios and Specifications
13.4.3 Ultimovacs Peptide Vaccine for Tumor Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Ultimovacs Main Business Overview
13.4.5 Ultimovacs Latest Developments
13.5 Marker Therapeutics, Inc.
13.5.1 Marker Therapeutics, Inc. Company Information
13.5.2 Marker Therapeutics, Inc. Peptide Vaccine for Tumor Product Portfolios and Specifications
13.5.3 Marker Therapeutics, Inc. Peptide Vaccine for Tumor Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Marker Therapeutics, Inc. Main Business Overview
13.5.5 Marker Therapeutics, Inc. Latest Developments
13.6 Immatics
13.6.1 Immatics Company Information
13.6.2 Immatics Peptide Vaccine for Tumor Product Portfolios and Specifications
13.6.3 Immatics Peptide Vaccine for Tumor Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Immatics Main Business Overview
13.6.5 Immatics Latest Developments
13.7 OncoPep
13.7.1 OncoPep Company Information
13.7.2 OncoPep Peptide Vaccine for Tumor Product Portfolios and Specifications
13.7.3 OncoPep Peptide Vaccine for Tumor Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 OncoPep Main Business Overview
13.7.5 OncoPep Latest Developments
13.8 Anergis
13.8.1 Anergis Company Information
13.8.2 Anergis Peptide Vaccine for Tumor Product Portfolios and Specifications
13.8.3 Anergis Peptide Vaccine for Tumor Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Anergis Main Business Overview
13.8.5 Anergis Latest Developments
13.9 Sellas Life Sciences
13.9.1 Sellas Life Sciences Company Information
13.9.2 Sellas Life Sciences Peptide Vaccine for Tumor Product Portfolios and Specifications
13.9.3 Sellas Life Sciences Peptide Vaccine for Tumor Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Sellas Life Sciences Main Business Overview
13.9.5 Sellas Life Sciences Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Peptide Vaccine for Tumor Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Peptide Vaccine for Tumor Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Synthetic Polypeptide Vaccines
Table 4. Major Players of Recombinant Polypeptide Vaccine
Table 5. Major Players of Others
Table 6. Global Peptide Vaccine for Tumor Sales by Type (2021-2026) & (K Dose)
Table 7. Global Peptide Vaccine for Tumor Sales Market Share by Type (2021-2026)
Table 8. Global Peptide Vaccine for Tumor Revenue by Type (2021-2026) & ($ million)
Table 9. Global Peptide Vaccine for Tumor Revenue Market Share by Type (2021-2026)
Table 10. Global Peptide Vaccine for Tumor Sale Price by Type (2021-2026) & (US$/Dose)
Table 11. Global Peptide Vaccine for Tumor Sale by Application (2021-2026) & (K Dose)
Table 12. Global Peptide Vaccine for Tumor Sale Market Share by Application (2021-2026)
Table 13. Global Peptide Vaccine for Tumor Revenue by Application (2021-2026) & ($ million)
Table 14. Global Peptide Vaccine for Tumor Revenue Market Share by Application (2021-2026)
Table 15. Global Peptide Vaccine for Tumor Sale Price by Application (2021-2026) & (US$/Dose)
Table 16. Global Peptide Vaccine for Tumor Sales by Company (2021-2026) & (K Dose)
Table 17. Global Peptide Vaccine for Tumor Sales Market Share by Company (2021-2026)
Table 18. Global Peptide Vaccine for Tumor Revenue by Company (2021-2026) & ($ millions)
Table 19. Global Peptide Vaccine for Tumor Revenue Market Share by Company (2021-2026)
Table 20. Global Peptide Vaccine for Tumor Sale Price by Company (2021-2026) & (US$/Dose)
Table 21. Key Manufacturers Peptide Vaccine for Tumor Producing Area Distribution and Sales Area
Table 22. Players Peptide Vaccine for Tumor Products Offered
Table 23. Peptide Vaccine for Tumor Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 24. New Products and Potential Entrants
Table 25. Market M&A Activity & Strategy
Table 26. Global Peptide Vaccine for Tumor Sales by Geographic Region (2021-2026) & (K Dose)
Table 27. Global Peptide Vaccine for Tumor Sales Market Share Geographic Region (2021-2026)
Table 28. Global Peptide Vaccine for Tumor Revenue by Geographic Region (2021-2026) & ($ millions)
Table 29. Global Peptide Vaccine for Tumor Revenue Market Share by Geographic Region (2021-2026)
Table 30. Global Peptide Vaccine for Tumor Sales by Country/Region (2021-2026) & (K Dose)
Table 31. Global Peptide Vaccine for Tumor Sales Market Share by Country/Region (2021-2026)
Table 32. Global Peptide Vaccine for Tumor Revenue by Country/Region (2021-2026) & ($ millions)
Table 33. Global Peptide Vaccine for Tumor Revenue Market Share by Country/Region (2021-2026)
Table 34. Americas Peptide Vaccine for Tumor Sales by Country (2021-2026) & (K Dose)
Table 35. Americas Peptide Vaccine for Tumor Sales Market Share by Country (2021-2026)
Table 36. Americas Peptide Vaccine for Tumor Revenue by Country (2021-2026) & ($ millions)
Table 37. Americas Peptide Vaccine for Tumor Sales by Type (2021-2026) & (K Dose)
Table 38. Americas Peptide Vaccine for Tumor Sales by Application (2021-2026) & (K Dose)
Table 39. APAC Peptide Vaccine for Tumor Sales by Region (2021-2026) & (K Dose)
Table 40. APAC Peptide Vaccine for Tumor Sales Market Share by Region (2021-2026)
Table 41. APAC Peptide Vaccine for Tumor Revenue by Region (2021-2026) & ($ millions)
Table 42. APAC Peptide Vaccine for Tumor Sales by Type (2021-2026) & (K Dose)
Table 43. APAC Peptide Vaccine for Tumor Sales by Application (2021-2026) & (K Dose)
Table 44. Europe Peptide Vaccine for Tumor Sales by Country (2021-2026) & (K Dose)
Table 45. Europe Peptide Vaccine for Tumor Revenue by Country (2021-2026) & ($ millions)
Table 46. Europe Peptide Vaccine for Tumor Sales by Type (2021-2026) & (K Dose)
Table 47. Europe Peptide Vaccine for Tumor Sales by Application (2021-2026) & (K Dose)
Table 48. Middle East & Africa Peptide Vaccine for Tumor Sales by Country (2021-2026) & (K Dose)
Table 49. Middle East & Africa Peptide Vaccine for Tumor Revenue Market Share by Country (2021-2026)
Table 50. Middle East & Africa Peptide Vaccine for Tumor Sales by Type (2021-2026) & (K Dose)
Table 51. Middle East & Africa Peptide Vaccine for Tumor Sales by Application (2021-2026) & (K Dose)
Table 52. Key Market Drivers & Growth Opportunities of Peptide Vaccine for Tumor
Table 53. Key Market Challenges & Risks of Peptide Vaccine for Tumor
Table 54. Key Industry Trends of Peptide Vaccine for Tumor
Table 55. Peptide Vaccine for Tumor Raw Material
Table 56. Key Suppliers of Raw Materials
Table 57. Peptide Vaccine for Tumor Distributors List
Table 58. Peptide Vaccine for Tumor Customer List
Table 59. Global Peptide Vaccine for Tumor Sales Forecast by Region (2027-2032) & (K Dose)
Table 60. Global Peptide Vaccine for Tumor Revenue Forecast by Region (2027-2032) & ($ millions)
Table 61. Americas Peptide Vaccine for Tumor Sales Forecast by Country (2027-2032) & (K Dose)
Table 62. Americas Peptide Vaccine for Tumor Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 63. APAC Peptide Vaccine for Tumor Sales Forecast by Region (2027-2032) & (K Dose)
Table 64. APAC Peptide Vaccine for Tumor Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 65. Europe Peptide Vaccine for Tumor Sales Forecast by Country (2027-2032) & (K Dose)
Table 66. Europe Peptide Vaccine for Tumor Revenue Forecast by Country (2027-2032) & ($ millions)
Table 67. Middle East & Africa Peptide Vaccine for Tumor Sales Forecast by Country (2027-2032) & (K Dose)
Table 68. Middle East & Africa Peptide Vaccine for Tumor Revenue Forecast by Country (2027-2032) & ($ millions)
Table 69. Global Peptide Vaccine for Tumor Sales Forecast by Type (2027-2032) & (K Dose)
Table 70. Global Peptide Vaccine for Tumor Revenue Forecast by Type (2027-2032) & ($ millions)
Table 71. Global Peptide Vaccine for Tumor Sales Forecast by Application (2027-2032) & (K Dose)
Table 72. Global Peptide Vaccine for Tumor Revenue Forecast by Application (2027-2032) & ($ millions)
Table 73. AmbioPharm Basic Information, Peptide Vaccine for Tumor Manufacturing Base, Sales Area and Its Competitors
Table 74. AmbioPharm Peptide Vaccine for Tumor Product Portfolios and Specifications
Table 75. AmbioPharm Peptide Vaccine for Tumor Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 76. AmbioPharm Main Business
Table 77. AmbioPharm Latest Developments
Table 78. Almac Basic Information, Peptide Vaccine for Tumor Manufacturing Base, Sales Area and Its Competitors
Table 79. Almac Peptide Vaccine for Tumor Product Portfolios and Specifications
Table 80. Almac Peptide Vaccine for Tumor Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 81. Almac Main Business
Table 82. Almac Latest Developments
Table 83. ACT Basic Information, Peptide Vaccine for Tumor Manufacturing Base, Sales Area and Its Competitors
Table 84. ACT Peptide Vaccine for Tumor Product Portfolios and Specifications
Table 85. ACT Peptide Vaccine for Tumor Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 86. ACT Main Business
Table 87. ACT Latest Developments
Table 88. Ultimovacs Basic Information, Peptide Vaccine for Tumor Manufacturing Base, Sales Area and Its Competitors
Table 89. Ultimovacs Peptide Vaccine for Tumor Product Portfolios and Specifications
Table 90. Ultimovacs Peptide Vaccine for Tumor Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 91. Ultimovacs Main Business
Table 92. Ultimovacs Latest Developments
Table 93. Marker Therapeutics, Inc. Basic Information, Peptide Vaccine for Tumor Manufacturing Base, Sales Area and Its Competitors
Table 94. Marker Therapeutics, Inc. Peptide Vaccine for Tumor Product Portfolios and Specifications
Table 95. Marker Therapeutics, Inc. Peptide Vaccine for Tumor Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 96. Marker Therapeutics, Inc. Main Business
Table 97. Marker Therapeutics, Inc. Latest Developments
Table 98. Immatics Basic Information, Peptide Vaccine for Tumor Manufacturing Base, Sales Area and Its Competitors
Table 99. Immatics Peptide Vaccine for Tumor Product Portfolios and Specifications
Table 100. Immatics Peptide Vaccine for Tumor Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 101. Immatics Main Business
Table 102. Immatics Latest Developments
Table 103. OncoPep Basic Information, Peptide Vaccine for Tumor Manufacturing Base, Sales Area and Its Competitors
Table 104. OncoPep Peptide Vaccine for Tumor Product Portfolios and Specifications
Table 105. OncoPep Peptide Vaccine for Tumor Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 106. OncoPep Main Business
Table 107. OncoPep Latest Developments
Table 108. Anergis Basic Information, Peptide Vaccine for Tumor Manufacturing Base, Sales Area and Its Competitors
Table 109. Anergis Peptide Vaccine for Tumor Product Portfolios and Specifications
Table 110. Anergis Peptide Vaccine for Tumor Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 111. Anergis Main Business
Table 112. Anergis Latest Developments
Table 113. Sellas Life Sciences Basic Information, Peptide Vaccine for Tumor Manufacturing Base, Sales Area and Its Competitors
Table 114. Sellas Life Sciences Peptide Vaccine for Tumor Product Portfolios and Specifications
Table 115. Sellas Life Sciences Peptide Vaccine for Tumor Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 116. Sellas Life Sciences Main Business
Table 117. Sellas Life Sciences Latest Developments
Table 1. Peptide Vaccine for Tumor Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Peptide Vaccine for Tumor Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Synthetic Polypeptide Vaccines
Table 4. Major Players of Recombinant Polypeptide Vaccine
Table 5. Major Players of Others
Table 6. Global Peptide Vaccine for Tumor Sales by Type (2021-2026) & (K Dose)
Table 7. Global Peptide Vaccine for Tumor Sales Market Share by Type (2021-2026)
Table 8. Global Peptide Vaccine for Tumor Revenue by Type (2021-2026) & ($ million)
Table 9. Global Peptide Vaccine for Tumor Revenue Market Share by Type (2021-2026)
Table 10. Global Peptide Vaccine for Tumor Sale Price by Type (2021-2026) & (US$/Dose)
Table 11. Global Peptide Vaccine for Tumor Sale by Application (2021-2026) & (K Dose)
Table 12. Global Peptide Vaccine for Tumor Sale Market Share by Application (2021-2026)
Table 13. Global Peptide Vaccine for Tumor Revenue by Application (2021-2026) & ($ million)
Table 14. Global Peptide Vaccine for Tumor Revenue Market Share by Application (2021-2026)
Table 15. Global Peptide Vaccine for Tumor Sale Price by Application (2021-2026) & (US$/Dose)
Table 16. Global Peptide Vaccine for Tumor Sales by Company (2021-2026) & (K Dose)
Table 17. Global Peptide Vaccine for Tumor Sales Market Share by Company (2021-2026)
Table 18. Global Peptide Vaccine for Tumor Revenue by Company (2021-2026) & ($ millions)
Table 19. Global Peptide Vaccine for Tumor Revenue Market Share by Company (2021-2026)
Table 20. Global Peptide Vaccine for Tumor Sale Price by Company (2021-2026) & (US$/Dose)
Table 21. Key Manufacturers Peptide Vaccine for Tumor Producing Area Distribution and Sales Area
Table 22. Players Peptide Vaccine for Tumor Products Offered
Table 23. Peptide Vaccine for Tumor Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 24. New Products and Potential Entrants
Table 25. Market M&A Activity & Strategy
Table 26. Global Peptide Vaccine for Tumor Sales by Geographic Region (2021-2026) & (K Dose)
Table 27. Global Peptide Vaccine for Tumor Sales Market Share Geographic Region (2021-2026)
Table 28. Global Peptide Vaccine for Tumor Revenue by Geographic Region (2021-2026) & ($ millions)
Table 29. Global Peptide Vaccine for Tumor Revenue Market Share by Geographic Region (2021-2026)
Table 30. Global Peptide Vaccine for Tumor Sales by Country/Region (2021-2026) & (K Dose)
Table 31. Global Peptide Vaccine for Tumor Sales Market Share by Country/Region (2021-2026)
Table 32. Global Peptide Vaccine for Tumor Revenue by Country/Region (2021-2026) & ($ millions)
Table 33. Global Peptide Vaccine for Tumor Revenue Market Share by Country/Region (2021-2026)
Table 34. Americas Peptide Vaccine for Tumor Sales by Country (2021-2026) & (K Dose)
Table 35. Americas Peptide Vaccine for Tumor Sales Market Share by Country (2021-2026)
Table 36. Americas Peptide Vaccine for Tumor Revenue by Country (2021-2026) & ($ millions)
Table 37. Americas Peptide Vaccine for Tumor Sales by Type (2021-2026) & (K Dose)
Table 38. Americas Peptide Vaccine for Tumor Sales by Application (2021-2026) & (K Dose)
Table 39. APAC Peptide Vaccine for Tumor Sales by Region (2021-2026) & (K Dose)
Table 40. APAC Peptide Vaccine for Tumor Sales Market Share by Region (2021-2026)
Table 41. APAC Peptide Vaccine for Tumor Revenue by Region (2021-2026) & ($ millions)
Table 42. APAC Peptide Vaccine for Tumor Sales by Type (2021-2026) & (K Dose)
Table 43. APAC Peptide Vaccine for Tumor Sales by Application (2021-2026) & (K Dose)
Table 44. Europe Peptide Vaccine for Tumor Sales by Country (2021-2026) & (K Dose)
Table 45. Europe Peptide Vaccine for Tumor Revenue by Country (2021-2026) & ($ millions)
Table 46. Europe Peptide Vaccine for Tumor Sales by Type (2021-2026) & (K Dose)
Table 47. Europe Peptide Vaccine for Tumor Sales by Application (2021-2026) & (K Dose)
Table 48. Middle East & Africa Peptide Vaccine for Tumor Sales by Country (2021-2026) & (K Dose)
Table 49. Middle East & Africa Peptide Vaccine for Tumor Revenue Market Share by Country (2021-2026)
Table 50. Middle East & Africa Peptide Vaccine for Tumor Sales by Type (2021-2026) & (K Dose)
Table 51. Middle East & Africa Peptide Vaccine for Tumor Sales by Application (2021-2026) & (K Dose)
Table 52. Key Market Drivers & Growth Opportunities of Peptide Vaccine for Tumor
Table 53. Key Market Challenges & Risks of Peptide Vaccine for Tumor
Table 54. Key Industry Trends of Peptide Vaccine for Tumor
Table 55. Peptide Vaccine for Tumor Raw Material
Table 56. Key Suppliers of Raw Materials
Table 57. Peptide Vaccine for Tumor Distributors List
Table 58. Peptide Vaccine for Tumor Customer List
Table 59. Global Peptide Vaccine for Tumor Sales Forecast by Region (2027-2032) & (K Dose)
Table 60. Global Peptide Vaccine for Tumor Revenue Forecast by Region (2027-2032) & ($ millions)
Table 61. Americas Peptide Vaccine for Tumor Sales Forecast by Country (2027-2032) & (K Dose)
Table 62. Americas Peptide Vaccine for Tumor Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 63. APAC Peptide Vaccine for Tumor Sales Forecast by Region (2027-2032) & (K Dose)
Table 64. APAC Peptide Vaccine for Tumor Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 65. Europe Peptide Vaccine for Tumor Sales Forecast by Country (2027-2032) & (K Dose)
Table 66. Europe Peptide Vaccine for Tumor Revenue Forecast by Country (2027-2032) & ($ millions)
Table 67. Middle East & Africa Peptide Vaccine for Tumor Sales Forecast by Country (2027-2032) & (K Dose)
Table 68. Middle East & Africa Peptide Vaccine for Tumor Revenue Forecast by Country (2027-2032) & ($ millions)
Table 69. Global Peptide Vaccine for Tumor Sales Forecast by Type (2027-2032) & (K Dose)
Table 70. Global Peptide Vaccine for Tumor Revenue Forecast by Type (2027-2032) & ($ millions)
Table 71. Global Peptide Vaccine for Tumor Sales Forecast by Application (2027-2032) & (K Dose)
Table 72. Global Peptide Vaccine for Tumor Revenue Forecast by Application (2027-2032) & ($ millions)
Table 73. AmbioPharm Basic Information, Peptide Vaccine for Tumor Manufacturing Base, Sales Area and Its Competitors
Table 74. AmbioPharm Peptide Vaccine for Tumor Product Portfolios and Specifications
Table 75. AmbioPharm Peptide Vaccine for Tumor Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 76. AmbioPharm Main Business
Table 77. AmbioPharm Latest Developments
Table 78. Almac Basic Information, Peptide Vaccine for Tumor Manufacturing Base, Sales Area and Its Competitors
Table 79. Almac Peptide Vaccine for Tumor Product Portfolios and Specifications
Table 80. Almac Peptide Vaccine for Tumor Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 81. Almac Main Business
Table 82. Almac Latest Developments
Table 83. ACT Basic Information, Peptide Vaccine for Tumor Manufacturing Base, Sales Area and Its Competitors
Table 84. ACT Peptide Vaccine for Tumor Product Portfolios and Specifications
Table 85. ACT Peptide Vaccine for Tumor Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 86. ACT Main Business
Table 87. ACT Latest Developments
Table 88. Ultimovacs Basic Information, Peptide Vaccine for Tumor Manufacturing Base, Sales Area and Its Competitors
Table 89. Ultimovacs Peptide Vaccine for Tumor Product Portfolios and Specifications
Table 90. Ultimovacs Peptide Vaccine for Tumor Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 91. Ultimovacs Main Business
Table 92. Ultimovacs Latest Developments
Table 93. Marker Therapeutics, Inc. Basic Information, Peptide Vaccine for Tumor Manufacturing Base, Sales Area and Its Competitors
Table 94. Marker Therapeutics, Inc. Peptide Vaccine for Tumor Product Portfolios and Specifications
Table 95. Marker Therapeutics, Inc. Peptide Vaccine for Tumor Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 96. Marker Therapeutics, Inc. Main Business
Table 97. Marker Therapeutics, Inc. Latest Developments
Table 98. Immatics Basic Information, Peptide Vaccine for Tumor Manufacturing Base, Sales Area and Its Competitors
Table 99. Immatics Peptide Vaccine for Tumor Product Portfolios and Specifications
Table 100. Immatics Peptide Vaccine for Tumor Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 101. Immatics Main Business
Table 102. Immatics Latest Developments
Table 103. OncoPep Basic Information, Peptide Vaccine for Tumor Manufacturing Base, Sales Area and Its Competitors
Table 104. OncoPep Peptide Vaccine for Tumor Product Portfolios and Specifications
Table 105. OncoPep Peptide Vaccine for Tumor Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 106. OncoPep Main Business
Table 107. OncoPep Latest Developments
Table 108. Anergis Basic Information, Peptide Vaccine for Tumor Manufacturing Base, Sales Area and Its Competitors
Table 109. Anergis Peptide Vaccine for Tumor Product Portfolios and Specifications
Table 110. Anergis Peptide Vaccine for Tumor Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 111. Anergis Main Business
Table 112. Anergis Latest Developments
Table 113. Sellas Life Sciences Basic Information, Peptide Vaccine for Tumor Manufacturing Base, Sales Area and Its Competitors
Table 114. Sellas Life Sciences Peptide Vaccine for Tumor Product Portfolios and Specifications
Table 115. Sellas Life Sciences Peptide Vaccine for Tumor Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 116. Sellas Life Sciences Main Business
Table 117. Sellas Life Sciences Latest Developments
LIST OF FIGURES
Figure 1. Picture of Peptide Vaccine for Tumor
Figure 2. Peptide Vaccine for Tumor Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Peptide Vaccine for Tumor Sales Growth Rate 2021-2032 (K Dose)
Figure 7. Global Peptide Vaccine for Tumor Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Peptide Vaccine for Tumor Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Peptide Vaccine for Tumor Sales Market Share by Country/Region (2025)
Figure 10. Peptide Vaccine for Tumor Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Synthetic Polypeptide Vaccines
Figure 12. Product Picture of Recombinant Polypeptide Vaccine
Figure 13. Product Picture of Others
Figure 14. Global Peptide Vaccine for Tumor Sales Market Share by Type in 2026
Figure 15. Global Peptide Vaccine for Tumor Revenue Market Share by Type (2021-2026)
Figure 16. Peptide Vaccine for Tumor Consumed in Infectious Disease Prevention
Figure 17. Global Peptide Vaccine for Tumor Market: Infectious Disease Prevention (2021-2026) & (K Dose)
Figure 18. Peptide Vaccine for Tumor Consumed in Cancer Immunotherapy
Figure 19. Global Peptide Vaccine for Tumor Market: Cancer Immunotherapy (2021-2026) & (K Dose)
Figure 20. Peptide Vaccine for Tumor Consumed in Others
Figure 21. Global Peptide Vaccine for Tumor Market: Others (2021-2026) & (K Dose)
Figure 22. Global Peptide Vaccine for Tumor Sale Market Share by Application (2025)
Figure 23. Global Peptide Vaccine for Tumor Revenue Market Share by Application in 2026
Figure 24. Peptide Vaccine for Tumor Sales by Company in 2026 (K Dose)
Figure 25. Global Peptide Vaccine for Tumor Sales Market Share by Company in 2026
Figure 26. Peptide Vaccine for Tumor Revenue by Company in 2026 ($ millions)
Figure 27. Global Peptide Vaccine for Tumor Revenue Market Share by Company in 2026
Figure 28. Global Peptide Vaccine for Tumor Sales Market Share by Geographic Region (2021-2026)
Figure 29. Global Peptide Vaccine for Tumor Revenue Market Share by Geographic Region in 2026
Figure 30. Americas Peptide Vaccine for Tumor Sales 2021-2026 (K Dose)
Figure 31. Americas Peptide Vaccine for Tumor Revenue 2021-2026 ($ millions)
Figure 32. APAC Peptide Vaccine for Tumor Sales 2021-2026 (K Dose)
Figure 33. APAC Peptide Vaccine for Tumor Revenue 2021-2026 ($ millions)
Figure 34. Europe Peptide Vaccine for Tumor Sales 2021-2026 (K Dose)
Figure 35. Europe Peptide Vaccine for Tumor Revenue 2021-2026 ($ millions)
Figure 36. Middle East & Africa Peptide Vaccine for Tumor Sales 2021-2026 (K Dose)
Figure 37. Middle East & Africa Peptide Vaccine for Tumor Revenue 2021-2026 ($ millions)
Figure 38. Americas Peptide Vaccine for Tumor Sales Market Share by Country in 2026
Figure 39. Americas Peptide Vaccine for Tumor Revenue Market Share by Country (2021-2026)
Figure 40. Americas Peptide Vaccine for Tumor Sales Market Share by Type (2021-2026)
Figure 41. Americas Peptide Vaccine for Tumor Sales Market Share by Application (2021-2026)
Figure 42. United States Peptide Vaccine for Tumor Revenue Growth 2021-2026 ($ millions)
Figure 43. Canada Peptide Vaccine for Tumor Revenue Growth 2021-2026 ($ millions)
Figure 44. Mexico Peptide Vaccine for Tumor Revenue Growth 2021-2026 ($ millions)
Figure 45. Brazil Peptide Vaccine for Tumor Revenue Growth 2021-2026 ($ millions)
Figure 46. APAC Peptide Vaccine for Tumor Sales Market Share by Region in 2026
Figure 47. APAC Peptide Vaccine for Tumor Revenue Market Share by Region (2021-2026)
Figure 48. APAC Peptide Vaccine for Tumor Sales Market Share by Type (2021-2026)
Figure 49. APAC Peptide Vaccine for Tumor Sales Market Share by Application (2021-2026)
Figure 50. China Peptide Vaccine for Tumor Revenue Growth 2021-2026 ($ millions)
Figure 51. Japan Peptide Vaccine for Tumor Revenue Growth 2021-2026 ($ millions)
Figure 52. South Korea Peptide Vaccine for Tumor Revenue Growth 2021-2026 ($ millions)
Figure 53. Southeast Asia Peptide Vaccine for Tumor Revenue Growth 2021-2026 ($ millions)
Figure 54. India Peptide Vaccine for Tumor Revenue Growth 2021-2026 ($ millions)
Figure 55. Australia Peptide Vaccine for Tumor Revenue Growth 2021-2026 ($ millions)
Figure 56. China Taiwan Peptide Vaccine for Tumor Revenue Growth 2021-2026 ($ millions)
Figure 57. Europe Peptide Vaccine for Tumor Sales Market Share by Country in 2026
Figure 58. Europe Peptide Vaccine for Tumor Revenue Market Share by Country (2021-2026)
Figure 59. Europe Peptide Vaccine for Tumor Sales Market Share by Type (2021-2026)
Figure 60. Europe Peptide Vaccine for Tumor Sales Market Share by Application (2021-2026)
Figure 61. Germany Peptide Vaccine for Tumor Revenue Growth 2021-2026 ($ millions)
Figure 62. France Peptide Vaccine for Tumor Revenue Growth 2021-2026 ($ millions)
Figure 63. UK Peptide Vaccine for Tumor Revenue Growth 2021-2026 ($ millions)
Figure 64. Italy Peptide Vaccine for Tumor Revenue Growth 2021-2026 ($ millions)
Figure 65. Russia Peptide Vaccine for Tumor Revenue Growth 2021-2026 ($ millions)
Figure 66. Middle East & Africa Peptide Vaccine for Tumor Sales Market Share by Country (2021-2026)
Figure 67. Middle East & Africa Peptide Vaccine for Tumor Sales Market Share by Type (2021-2026)
Figure 68. Middle East & Africa Peptide Vaccine for Tumor Sales Market Share by Application (2021-2026)
Figure 69. Egypt Peptide Vaccine for Tumor Revenue Growth 2021-2026 ($ millions)
Figure 70. South Africa Peptide Vaccine for Tumor Revenue Growth 2021-2026 ($ millions)
Figure 71. Israel Peptide Vaccine for Tumor Revenue Growth 2021-2026 ($ millions)
Figure 72. Turkey Peptide Vaccine for Tumor Revenue Growth 2021-2026 ($ millions)
Figure 73. GCC Countries Peptide Vaccine for Tumor Revenue Growth 2021-2026 ($ millions)
Figure 74. Manufacturing Cost Structure Analysis of Peptide Vaccine for Tumor in 2026
Figure 75. Manufacturing Process Analysis of Peptide Vaccine for Tumor
Figure 76. Industry Chain Structure of Peptide Vaccine for Tumor
Figure 77. Channels of Distribution
Figure 78. Global Peptide Vaccine for Tumor Sales Market Forecast by Region (2027-2032)
Figure 79. Global Peptide Vaccine for Tumor Revenue Market Share Forecast by Region (2027-2032)
Figure 80. Global Peptide Vaccine for Tumor Sales Market Share Forecast by Type (2027-2032)
Figure 81. Global Peptide Vaccine for Tumor Revenue Market Share Forecast by Type (2027-2032)
Figure 82. Global Peptide Vaccine for Tumor Sales Market Share Forecast by Application (2027-2032)
Figure 83. Global Peptide Vaccine for Tumor Revenue Market Share Forecast by Application (2027-2032)
Figure 1. Picture of Peptide Vaccine for Tumor
Figure 2. Peptide Vaccine for Tumor Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Peptide Vaccine for Tumor Sales Growth Rate 2021-2032 (K Dose)
Figure 7. Global Peptide Vaccine for Tumor Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Peptide Vaccine for Tumor Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Peptide Vaccine for Tumor Sales Market Share by Country/Region (2025)
Figure 10. Peptide Vaccine for Tumor Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Synthetic Polypeptide Vaccines
Figure 12. Product Picture of Recombinant Polypeptide Vaccine
Figure 13. Product Picture of Others
Figure 14. Global Peptide Vaccine for Tumor Sales Market Share by Type in 2026
Figure 15. Global Peptide Vaccine for Tumor Revenue Market Share by Type (2021-2026)
Figure 16. Peptide Vaccine for Tumor Consumed in Infectious Disease Prevention
Figure 17. Global Peptide Vaccine for Tumor Market: Infectious Disease Prevention (2021-2026) & (K Dose)
Figure 18. Peptide Vaccine for Tumor Consumed in Cancer Immunotherapy
Figure 19. Global Peptide Vaccine for Tumor Market: Cancer Immunotherapy (2021-2026) & (K Dose)
Figure 20. Peptide Vaccine for Tumor Consumed in Others
Figure 21. Global Peptide Vaccine for Tumor Market: Others (2021-2026) & (K Dose)
Figure 22. Global Peptide Vaccine for Tumor Sale Market Share by Application (2025)
Figure 23. Global Peptide Vaccine for Tumor Revenue Market Share by Application in 2026
Figure 24. Peptide Vaccine for Tumor Sales by Company in 2026 (K Dose)
Figure 25. Global Peptide Vaccine for Tumor Sales Market Share by Company in 2026
Figure 26. Peptide Vaccine for Tumor Revenue by Company in 2026 ($ millions)
Figure 27. Global Peptide Vaccine for Tumor Revenue Market Share by Company in 2026
Figure 28. Global Peptide Vaccine for Tumor Sales Market Share by Geographic Region (2021-2026)
Figure 29. Global Peptide Vaccine for Tumor Revenue Market Share by Geographic Region in 2026
Figure 30. Americas Peptide Vaccine for Tumor Sales 2021-2026 (K Dose)
Figure 31. Americas Peptide Vaccine for Tumor Revenue 2021-2026 ($ millions)
Figure 32. APAC Peptide Vaccine for Tumor Sales 2021-2026 (K Dose)
Figure 33. APAC Peptide Vaccine for Tumor Revenue 2021-2026 ($ millions)
Figure 34. Europe Peptide Vaccine for Tumor Sales 2021-2026 (K Dose)
Figure 35. Europe Peptide Vaccine for Tumor Revenue 2021-2026 ($ millions)
Figure 36. Middle East & Africa Peptide Vaccine for Tumor Sales 2021-2026 (K Dose)
Figure 37. Middle East & Africa Peptide Vaccine for Tumor Revenue 2021-2026 ($ millions)
Figure 38. Americas Peptide Vaccine for Tumor Sales Market Share by Country in 2026
Figure 39. Americas Peptide Vaccine for Tumor Revenue Market Share by Country (2021-2026)
Figure 40. Americas Peptide Vaccine for Tumor Sales Market Share by Type (2021-2026)
Figure 41. Americas Peptide Vaccine for Tumor Sales Market Share by Application (2021-2026)
Figure 42. United States Peptide Vaccine for Tumor Revenue Growth 2021-2026 ($ millions)
Figure 43. Canada Peptide Vaccine for Tumor Revenue Growth 2021-2026 ($ millions)
Figure 44. Mexico Peptide Vaccine for Tumor Revenue Growth 2021-2026 ($ millions)
Figure 45. Brazil Peptide Vaccine for Tumor Revenue Growth 2021-2026 ($ millions)
Figure 46. APAC Peptide Vaccine for Tumor Sales Market Share by Region in 2026
Figure 47. APAC Peptide Vaccine for Tumor Revenue Market Share by Region (2021-2026)
Figure 48. APAC Peptide Vaccine for Tumor Sales Market Share by Type (2021-2026)
Figure 49. APAC Peptide Vaccine for Tumor Sales Market Share by Application (2021-2026)
Figure 50. China Peptide Vaccine for Tumor Revenue Growth 2021-2026 ($ millions)
Figure 51. Japan Peptide Vaccine for Tumor Revenue Growth 2021-2026 ($ millions)
Figure 52. South Korea Peptide Vaccine for Tumor Revenue Growth 2021-2026 ($ millions)
Figure 53. Southeast Asia Peptide Vaccine for Tumor Revenue Growth 2021-2026 ($ millions)
Figure 54. India Peptide Vaccine for Tumor Revenue Growth 2021-2026 ($ millions)
Figure 55. Australia Peptide Vaccine for Tumor Revenue Growth 2021-2026 ($ millions)
Figure 56. China Taiwan Peptide Vaccine for Tumor Revenue Growth 2021-2026 ($ millions)
Figure 57. Europe Peptide Vaccine for Tumor Sales Market Share by Country in 2026
Figure 58. Europe Peptide Vaccine for Tumor Revenue Market Share by Country (2021-2026)
Figure 59. Europe Peptide Vaccine for Tumor Sales Market Share by Type (2021-2026)
Figure 60. Europe Peptide Vaccine for Tumor Sales Market Share by Application (2021-2026)
Figure 61. Germany Peptide Vaccine for Tumor Revenue Growth 2021-2026 ($ millions)
Figure 62. France Peptide Vaccine for Tumor Revenue Growth 2021-2026 ($ millions)
Figure 63. UK Peptide Vaccine for Tumor Revenue Growth 2021-2026 ($ millions)
Figure 64. Italy Peptide Vaccine for Tumor Revenue Growth 2021-2026 ($ millions)
Figure 65. Russia Peptide Vaccine for Tumor Revenue Growth 2021-2026 ($ millions)
Figure 66. Middle East & Africa Peptide Vaccine for Tumor Sales Market Share by Country (2021-2026)
Figure 67. Middle East & Africa Peptide Vaccine for Tumor Sales Market Share by Type (2021-2026)
Figure 68. Middle East & Africa Peptide Vaccine for Tumor Sales Market Share by Application (2021-2026)
Figure 69. Egypt Peptide Vaccine for Tumor Revenue Growth 2021-2026 ($ millions)
Figure 70. South Africa Peptide Vaccine for Tumor Revenue Growth 2021-2026 ($ millions)
Figure 71. Israel Peptide Vaccine for Tumor Revenue Growth 2021-2026 ($ millions)
Figure 72. Turkey Peptide Vaccine for Tumor Revenue Growth 2021-2026 ($ millions)
Figure 73. GCC Countries Peptide Vaccine for Tumor Revenue Growth 2021-2026 ($ millions)
Figure 74. Manufacturing Cost Structure Analysis of Peptide Vaccine for Tumor in 2026
Figure 75. Manufacturing Process Analysis of Peptide Vaccine for Tumor
Figure 76. Industry Chain Structure of Peptide Vaccine for Tumor
Figure 77. Channels of Distribution
Figure 78. Global Peptide Vaccine for Tumor Sales Market Forecast by Region (2027-2032)
Figure 79. Global Peptide Vaccine for Tumor Revenue Market Share Forecast by Region (2027-2032)
Figure 80. Global Peptide Vaccine for Tumor Sales Market Share Forecast by Type (2027-2032)
Figure 81. Global Peptide Vaccine for Tumor Revenue Market Share Forecast by Type (2027-2032)
Figure 82. Global Peptide Vaccine for Tumor Sales Market Share Forecast by Application (2027-2032)
Figure 83. Global Peptide Vaccine for Tumor Revenue Market Share Forecast by Application (2027-2032)
